Inrig Jula 4
4 · Travere Therapeutics, Inc. · Filed Apr 15, 2026
Research Summary
AI-generated summary of this filing
Travere (TVTX) CMO Jula Sells Shares After PSU Vest
What Happened
Chief Medical Officer Jula Inrig received 14,000 performance restricted stock units (PSUs) that vested on April 13, 2026 following the issuer's confirmation of FDA approval for FILSPARI (sparsentan) in FSGS. Following vesting, Jula sold a total of 8,233 shares in two open-market transactions (7,215 shares on 2026-04-14 at $41.93 and 1,018 shares on 2026-04-15 at $42.61), generating reported proceeds of $302,516 and $43,377 respectively (combined ≈ $345,893). The award itself is reported as $0 cash consideration since it was a restricted stock unit settlement.
Key Details
- Award: 14,000 PSUs vested on 2026-04-13 (grant originally made Jan 31, 2025). [Footnote F1]
- Sales:
- 2026-04-14: 7,215 shares sold @ $41.93 = $302,516. (Includes mandated sell-to-cover for taxes.) [F2]
- 2026-04-15: 1,018 shares sold @ $42.61 = $43,377. (Executed under a 10b5‑1 plan adopted 2025‑05‑28; includes tax-cover shares.) [F3]
- These sales include shares sold to cover tax withholding required upon PSU settlement (sell-to-cover), not solely discretionary trades.
- Shares owned after the reported transactions: not specified in the filing.
- Filing: Reported on Form 4 with period of report 2026‑04‑13 and filed 2026‑04‑15; no late filing indicated in the document.
Context
- This sequence (award vesting followed by sell-to-cover and additional plan sales) is common when equity awards settle: the award increases holdings but some shares are immediately sold to satisfy taxes or under pre-set sale plans. These sales do not necessarily signal the insider’s discretionary view on the company.
Insider Transaction Report
Form 4
Inrig Jula
CHIEF MEDICAL OFFICER
Transactions
- Award
Common Stock
[F1]2026-04-13+14,000→ 119,706 total - Sale
Common Stock
[F2]2026-04-14$41.93/sh−7,215$302,516→ 112,491 total - Sale
Common Stock
[F3]2026-04-15$42.61/sh−1,018$43,377→ 111,473 total
Footnotes (3)
- [F1]On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
- [F2]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
- [F3]This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact|2026-04-15